ArticleNature communications2025
Improved analysis of in vivo drug combination experiments with a comprehensive statistical framework and web-tool.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- In Vitro Effects of an Olive Polyphenol-Bromelain Formulation on U87MG Glioblastoma Cells: Viability, Cell-Cycle Distribution, Cytokine Release, and Total Antioxidant Capacity.Molecules (Basel, Switzerland) · 2026Article
- Visualized self-propelled nanorobots overcome tumor barriers for boosted photothermal-nanocatalytic synergistic therapy against triple-negative breast cancer.Journal of nanobiotechnology · 2026Article
- Chemically Masked aPD-L1-Sialidase Conjugate for Tumor-Specific Desialylation and Immunotherapy.Angewandte Chemie (International ed. in English) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Drug combination therapy is often required to overcome the limited benefits of monotherapy in cancer treatment. While several tools exist for in vitro drug synergy screening and assessment, there is a lack of integrated methods for statistical analysis of in vivo combination experiments. To fill this gap, we present SynergyLMM, a comprehensive modeling and design framework for evaluating drug combination effects in preclinical in vivo studies. Unlike other methods, SynergyLMM accommodates complex experimental designs, including multi-drug combinations, and offers practical options for statistical analysis of both synergy and antagonism through longitudinal drug interaction analysis, including model diagnostics and statistical power analysis. These functionalities allow researchers to optimize study designs and determine an appropriate number of animals and follow-up time points required to achieve sufficient synergy and statistical power. SynergyLMM is implemented as an easy-to-use web-application, making it widely accessible for researchers without programming skills. We demonstrate the versatility and added value of SynergyLMM through its applications to various experimental setups and treatment experiments with chemo-, targeted- and immunotherapy. These case studies showcase its potential to improve robustness, statistical rigor and consistency of preclinical drug combination results, enabling a faster and safer transition from preclinical to clinical testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.